ReviewFrontiers in medicine2017
Pathogen Inactivation of Cellular Blood Products-An Additional Safety Layer in Transfusion Medicine.
Review in Frontiers in medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Retention of critical platelet hemostatic functions of amotosalen-UVA pathogen-reduced cryoprecipitated fibrinogen complex.Transfusion · 2026Article
- 405 nm violet-blue light inactivates hepatitis C cell culture virus (HCVcc) in ex vivo human platelet concentrates and plasma.Scientific reports · 2024Article
- Microbial reduction of prebagged human plasma using 405 nm light and its effects on coagulation factors.AMB Express · 2024Article
- Article
- Transfusion-Transmitted Disorders 2023 with Special Attention to Bone Marrow Transplant Patients.Pathogens (Basel, Switzerland) · 2023Review
- Requests for Directed Blood Donations.Pediatrics · 2023Article
- Changes in hemoglobin oxidation and band 3 during blood storage impact oxygen sensing and mitochondrial bioenergetic pathways in the human pulmonary arterial endothelial cell model.Frontiers in physiology · 2023Article
- Article
- Assessing quality of blood components derived from whole blood treated with riboflavin and ultraviolet light and separated with a fully automated device.Blood transfusion = Trasfusione del sangue · 2022Article
- Hemoglobin Oxidation Reactions in Stored Blood.Antioxidants (Basel, Switzerland) · 2022Article
- The Missing Pieces to the Cold-Stored Platelet Puzzle.International journal of molecular sciences · 2022Review
- Assessing the global burden of hemorrhage: The global blood supply, deficits, and potential solutions.SAGE open medicine · 2021Review
- COVID-19: benefits and risks of passive immunotherapeutics.Human vaccines & immunotherapeutics · 2020Review
- Blood utilisation and transfusion reactions in adult patients transfused with conventional or pathogen-reduced platelets.British journal of haematology · 2020Article
- Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026).Transfusion · 2019Article
- How do we … integrate pathogen reduced platelets into our hospital blood bank inventory?Transfusion · 2019Article
- A Fatal Case of Septic Shock Secondary toCase reports in medicine · 2019Article
- Hemovigilance data: An effective approach for evaluating bacterial protection systems for platelet transfusions.Asian journal of transfusion scienceArticle
- Dengue seropositivity among blood donors in a tertiary hospital in Kerala, Southern India.Annals of African medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In line with current microbial risk reduction efforts, pathogen inactivation (PI) technologies for blood components promise to reduce the residual risk of known and emerging infectious agents. The implementation of PI of labile blood components is slowly but steadily increasing. This review discusses the relevance of PI for the field of transfusion medicine and describes the available and emerging PI technologies that can be used to treat cellular blood products such as platelet and red blood cell units. In collaboration with the French medical device manufacturer Macopharma, the German Red Cross Blood Services developed a new UVC light-based PI method for platelet units, which is currently being investigated in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.